Overview

Intravenous Immune Globulin (IVIG) to Prevent Neonatal Infection

Status:
Completed
Trial end date:
1991-03-01
Target enrollment:
Participant gender:
Summary
A controlled clinical trial was conducted at eight participating centers between January 1, 1988, and March 31, 1991. Patients were randomly assigned to an intravenous immune globulin group or a control group. There were two phases to the study (see below). During phase 1 the control infants received infusions of placebo. During phase 2 the control infants received no infusion therapy.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
NICHD Neonatal Research Network
Treatments:
Antibodies
gamma-Globulins
Immunoglobulins
Immunoglobulins, Intravenous
Rho(D) Immune Globulin